NHS批准新的乳腺癌药物Trqap,为有特定基因突变的病人提供希望。 The NHS approves new breast cancer drug Truqap, offering hope to patients with specific gene mutations.

联合王国的国民保健制度批准了一种新药物,即Capivasertib(Truqap),用于最常见的高级乳腺癌。 The NHS in the UK has approved a new drug, capivasertib (Truqap), for the most common type of advanced breast cancer. 药片由AstraZeneca制成,它阻断了异常蛋白,AKT, 导致癌症细胞成倍增加。 Made by AstraZeneca, the pill works by blocking an abnormal protein, AKT, that causes cancer cells to multiply. 它适用于PIK3CA、AKT1或PTEN基因中具有特定基因突变的病人,可以延长预期寿命,在癌症研究所研究多年后被视为一项重大进步。 Suitable for patients with specific genetic mutations in the PIK3CA, AKT1, or PTEN genes, it can extend life expectancy and is seen as a significant advancement following years of research by the Institute of Cancer Research.